Actinic Keratosis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
In Dermatology Visit with Me to Discuss
From time to time new treatments surface for any medical field, and the last couple of years have seen new treatments emerge, or new applications for familiar treatments. I wanted to summarize some of these New Therapies widely available remedies and encourage you to schedule a in Dermatology visit with me to discuss. Written by Board Certified Dermatologist James W. Young, DO, FAOCD Nicotinamide a significant reduction in melanoma in Antioxidants Nicotinamide (niacinamide) is a form high risk skin cancer patients at doses Green tea, pomegranate, delphinidin of vitamin B3. The deficiency of vitamin more than 600 and less than 4,000 IU and fisetin are all under current study for daily. B3 causes pellagra, a condition marked either oral or topical use in the reduction by 4D’s – (photo) Dermatitis, Dementia, Polypodium Leucotomos of the incidence of skin cancer, psoriasis Diarrhea and (if left untreated) Death. and other inflammatory disorders. I’ll be Polypodium leucotomos is a Central This deficiency is rare in developed sure to keep patients updated. countries, but is occasionally seen America fern that is available in several in alcoholism, dieting restrictions, or forms, most widely as Fernblock What Are My Own Thoughts? malabsorption syndromes. Nicotinamide (Amazon) or Heliocare (Walgreen’s and I take Vitamin D 1,000 IU and Heliocare does not cause the adverse effects of Amazon) and others. It is an antioxidant personally. Based on new research, I Nicotinic acid and is safe at doses up to that reduces free oxygen radicals and have also added Nicotinamide which 3,000mg daily. may reduce inflammation in eczema, dementia, sunburn, psoriasis, and vitiligo. -
Actinic Keratoses Final Report
Actinic Keratoses Final Report Mark Helfand, MD, MPH Annalisa K. Gorman, MD Susan Mahon, MPH Benjamin K.S. Chan, MS Neil Swanson, MD Submitted to the Agency for Healthcare Research and Quality under contract 290-97-0018, task order no. 6 Oregon Health & Science University Evidence-based Practice Center 3181 SW Sam Jackson Park Road Portland, Oregon 97201 May 19, 2001 Actinic Keratoses Structured Abstract Objective: To examine evidence about the natural history and management of actinic keratoses (AKs). Search Strategy: We searched the MEDLINE database from January 1966 to January 2001, the Cochrane Controlled Trials Registry, and a bibliographic database of articles about skin cancer. We identified additional articles from reference lists and experts. Selection Criteria: We selected 45 articles that contained original data relevant to treatment of actinic keratoses, progression of AKs to squamous cell cancer (SCC ), means of identifying a high-risk group, or surveillance of patients with AKs to detect and treat SCCs early in their course. Data Collection and Analysis: We abstracted information from these studies to construct evidence tables. We also developed a simple mathematical model to examine whether estimates of the rate of progression of AK to SCC were consistent among studies. Finally, we analyzed data from the Medicare Statistical System to estimate the frequency of procedures attributable to AK among elderly beneficiaries. Main Results: The yearly rate of progression of an AK in an average-risk person in Australia is between 8 and 24 per 10,000. High-risk individuals with multiple AKs have progression rates as high as 12-30 percent over 3 years. -
What Are Basal and Squamous Cell Skin Cancers?
cancer.org | 1.800.227.2345 About Basal and Squamous Cell Skin Cancer Overview If you have been diagnosed with basal or squamous cell skin cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Are Basal and Squamous Cell Skin Cancers? Research and Statistics See the latest estimates for new cases of basal and squamous cell skin cancer and deaths in the US and what research is currently being done. ● Key Statistics for Basal and Squamous Cell Skin Cancers ● What’s New in Basal and Squamous Cell Skin Cancer Research? What Are Basal and Squamous Cell Skin Cancers? Basal and squamous cell skin cancers are the most common types of skin cancer. They start in the top layer of skin (the epidermis), and are often related to sun exposure. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer cells. To learn more about cancer and how it starts and spreads, see What Is Cancer?1 Where do skin cancers start? Most skin cancers start in the top layer of skin, called the epidermis. There are 3 main types of cells in this layer: ● Squamous cells: These are flat cells in the upper (outer) part of the epidermis, which are constantly shed as new ones form. When these cells grow out of control, they can develop into squamous cell skin cancer (also called squamous cell carcinoma). -
Thrombotic Thrombocytopenic Purpura Due to Checkpoint Inhibitors
Hindawi Case Reports in Hematology Volume 2018, Article ID 2464619, 4 pages https://doi.org/10.1155/2018/2464619 Case Report Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors Alexey Youssef,1 Nawara Kasso,2 Antonio Sergio Torloni,3 Michael Stanek,4 Tomislav Dragovich,5 Mark Gimbel,6 and Fade Mahmoud 6 1Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK 2Faculty of Medicine, Tishreen University, Lattakia, Syria 3Medical Director, Stem Cell )erapy, Apheresis, and Transfusion Medicine, Banner MD Anderson Cancer Center, Gilbert, AZ, USA 4Division of Hematology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA 5Chief, Division of Medical Oncology and Hematology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA 6)e T.W. Lewis Melanoma Center of Excellence, Banner MD Anderson Cancer Center, Gilbert, AZ, USA Correspondence should be addressed to Fade Mahmoud; [email protected] Received 16 September 2018; Revised 23 November 2018; Accepted 28 November 2018; Published 20 December 2018 Academic Editor: Akimichi Ohsaka Copyright © 2018 Alexey Youssef et al. ,is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Ipilimumab is a monoclonal antibody that enhances the efficacy of the immune system by targeting a cytotoxic T-lymphocyte- associated protein 4 (CTLA-4), which is a protein receptor that downregulates the immune system. Nivolumab is also a hu- manized monoclonal antibody that targets another protein receptor that prevents activated T cells from attacking the cancer; this receptor is called programmed cell death 1 (PD-1). -
Prior Authorization Criteria
PRIOR AUTHORIZATION CRITERIA Last Updated 09/01/2021 This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription drug benefit. Please verify drug coverage by checking your formulary and member handbook. Additional restrictions and exclusions may apply. If you have questions, please contact Providence Health Plan Customer Service at 503-574-7500 or 1-800-878-4445 (TTY: 711). Service is available five days a week, Monday through Friday, between 8 a.m. and 6 p.m. ACTINIC KERATOSIS AGENTS MEDICATION(S) CARAC, FLUOROURACIL 0.5% CREAM, IMIQUIMOD 3.75% CREAM, IMIQUIMOD 3.75% CREAM PUMP, KLISYRI, PICATO, TOLAK, ZYCLARA COVERED USES N/A EXCLUSION CRITERIA • Treatment of basal cell carcinoma or other skin cancers REQUIRED MEDICAL INFORMATION 1. For the treatment of Actinic Keratosis (AK): Documentation of trial and failure*, contraindication or intolerance to two of the following formulary, generic topical agents: a. Diclofenac 3% gel b. 5-fluorouracil 2% or 5% cream/solution c. Imiquimod 5% cream *An adequate trial and failure is defined as failure to achieve clearance of AK lesion(s) after adherence to recommended treatment dosing and duration Reauthorization: Requires documentation of a reduction in the number and/or size of lesions of AK and medical rationale for continuing therapy beyond recommended treatment course. 1. For the treatment of external genital and perianal warts/condyloma acuminate (Zyclara® 3.75% only): Documentation of trial and failure*, contraindication, or intolerance to formulary, generic imiquimod 5% cream. -
What to Expect Following Cryosurgery “Freezing”
What to Expect Following CryoSurgery “Freezing” What is Cryosurgery? Cryosurgery is a technique for removing skin lesions that primarily involve the surface of the skin, such as warts, seborrheic keratosis, or actinic keratosis. It is a quick method of removing the lesions with minimal scarring. The liquid nitrogen needs to be applied long enough to freeze the affected skin. By freezing the skin, a blister is created underneath the lesion. Ideally, as the new skin forms underneath the blister, the abnormal skin on the roof of the blister peels off. Occasionally if the lesion is very thick (such as a large wart), only the surface is blistered off. The base or residual lesion may need to be frozen at another visit. What to Expect Over the Next Few Weeks? During Treatment – Area being treated will sting, burn and then possibly itch. Immediately After Treatment – Area will be red sore and swollen. Next Day- Blister or blood blister has formed, tenderness starts to subside. Apply a Band-Aid if necessary. 7 Days- Surface is dark red/brown and scab-like. Apply Vaseline or an antibacterial ointment if necessary. 2 to 4 Weeks- The surface starts to peel off. This may be encouraged gently during bathing, when the scab is softened. No makeup should be applied until area is fully healed. How to Take care of the Skin after Cryosurgery A Band-Aid can be used for larger blisters or blisters in areas that are more likely to be traumatized- such as fingers and toes. If the area becomes dry or crusted, an ointment (Vaseline, Aquaphor) can also be applied. -
Lumps & Bumps: Approach to Common Dermatologic Neoplasms
Case-Based Approach to Common Dermatologic Neoplasms Patrick Retterbush, MD, FAAD Mohs Surgery & Dermatologic Oncology Associate Member of the American College of Mohs Surgery Private Practice: Lockman Dermatology January 27th 2018 Disclosure of Relevant Financial Relationships • I do not have any relevant financial relationships, commercial interests, and/or conflicts of interest regarding the content of this presentation. Goals/Objectives • Recognize common benign growths • Recognize common malignant growths • Useful clues & examination for evaluating melanocytic nevi and when to be concerned for melanoma/atypical moles • How to perform a basic skin biopsy and which method/type to choose • Basic treatment/when to refer Key Questions & Physical Examination Findings for a Growth History Physical Examination • How long has the lesion been • Describing a growth present? – flat or raised? • flat – macule (<1cm) or patch (>1cm) – years, months, weeks • raised – papule (<1cm) or plaque (>1cm) – nodule if deep (majority of lesion in • Has it changed? dermis/SQ) – Size – secondary descriptive features • scaly (hyperkeratosis, retention of strateum – Shape corneum) – Color • crusty (dried serum, blood, or pus on surface) • eroded or ulcerated (partial vs. full thickness – Symptoms – pain, bleeding, itch? epidermal loss) – Over what time frame? • color (skin colored, red, pigmented, pearly) • feel (hard or soft, mobile or fixed) • PMH: • size: i.e. 6 x 4mm – prior skin cancers • Look at the rest of the skin/region of skin • SCC/BCCs vs. melanoma -
An Uncommon but Often Lethal Skin Cancer Could Be That Individual Melanoma Patients Cancers Can Be Assessed by Gene Expression to Answer These Questions
HEALTH in the US and Australia are successfully actions of vitamin D, genetic alterations CONCLUSION treated by early surgery. However, 10 in the gene that controls the vitamin D At this point, the role of genetics in percent of melanomas have been highly receptor or related genes might reasonably melanoma is still unclear. While intense, recalcitrant to treatment. In the quest for be associated with poorer survival from intermittent sun exposure is clearly better understanding, multiple investiga- melanoma. It may be that individuals who important in the etiology of melanoma, tors are evaluating the role of genetic factors have aggressive melanoma have a different its importance for survival is not known. in survival. While excessive, intermittent set of genetic mutations from those com- Therefore, one cannot reliably say whether sun exposure is an important risk factor mon in more indolent melanomas. nature or nurture (i.e., behavior) is more Merkel Cell Carcinoma: for melanoma, it does not appear to be as- The genetic factors associated with important in either the etiology or the sociated with poorer melanoma survival. melanoma progression and survival are progression of melanoma. Hopefully, this Thus, genetic factors may be the culprit; it still being explored. While genetics in other uncertainty will continue to spur research An Uncommon But Often Lethal Skin Cancer could be that individual melanoma patients cancers can be assessed by gene expression to answer these questions. JAYASRI IYER, MD, AND PAUL NGHIEM, MD, PHD with a particular constellation of inherited analyses from fresh tumor tissue, this is ex- genetic mutations are those who have tremely difficult in melanoma, as primary DR. -
A Brighter Future for Psoriasis Patients Melanoma and Skin Cancer Center
Skin Health FROM THE MOUNT SINAI DEPARTMENT OF DERMATOLOGY FALL 2013 MESSAGE FROM THE CHAIR A Brighter Future for Psoriasis Patients By Mark G. Lebwohl, MD, Sol and Clara Kest Professor and Chair ount Sinai has been at the forefront of psoriasis research since Mthe 1980’s, when we introduced a topical combination regimen that remains the standard of care around the world even today. This consists of both a superpotent corticosteroid and a vitamin-D analog such as calcipotriene (Dovonex®) or calcitriol (Vectical®). The use of combination therapy led to the invention of Taclonex®, a popular and effective psoriasis formula that contains two topical agents. While refining the concept of combination therapy, we discovered that some topical preparations inactivate others, and subsequently we fostered the understanding that two or more ingredients, when applied together, must be shown to be compatible. In recent years this rule has been Dr. Mark G. Lebwohl embraced for all topical medicines, not just for psoriasis drugs. continued on page 4 BREAKING NEWS In This Issue Melanoma and Skin Cancer Center By Philip Friedlander, MD, PhD LASER HAIR REMOVAL Alan Kling, MD Page 2 he Tisch Cancer Institute is pleased to announce the creation of the Melanoma and TSkin Cancer Center, a virtual gathering place designed to provide a full array of medical LOOKING FAB THIS FALL resources to skin cancer patients. As part of its mission to deliver the highest quality of care, David S. Orentreich, MD the Center has assembled a team of leading specialists representing the fields of dermatology, Marina I. Peredo, MD medical oncology, surgery, dermatopathology, podiatry, and social work. -
Merkel Cell Carcinoma: Update and Review Timothy S
Merkel Cell Carcinoma: Update and Review Timothy S. Wang, MD,* Patrick J. Byrne, MD, FACS,† Lisa K. Jacobs, MD,‡ and Janis M. Taube, MD§ Merkel cell carcinoma (MCC) is a rare, aggressive, and often fatal cutaneous malignancy that is not usually suspected at the time of biopsy. Because of its increasing incidence and the discovery of a possible viral association, interest in MCC has escalated. Recent effort has broadened our breadth of knowledge regarding MCC and developed instruments to improve data collection and future study. This article provides an update on current thinking about the Merkel cell and MCC. Semin Cutan Med Surg 30:48-56 © 2011 Elsevier Inc. All rights reserved. erkel cell carcinoma (MCC) is a rare, aggressive, and current thinking, including novel insights into the Merkel Moften fatal cutaneous malignancy. It usually presents as cell; a review of the 2010 National Comprehensive Cancer a banal-appearing lesion and the diagnosis is rarely suspected Network (NCCN) therapeutic guidelines and new American at the time of biopsy. Because of increasing incidence and the Joint Committee on Cancer (AJCC) staging system; recom- discovery of a possible viral association, interest in MCC has mendations for pathologic reporting and new diagnostic escalated rapidly. codes; and the recently described Merkel cell polyoma virus From 1986 to 2001, the incidence of MCC in the United (MCPyV). States has tripled, and approximately 1500 new cases are diagnosed each year.1,2 MCC occurs most frequently among elderly white patients and perhaps slightly more commonly History in men. MCCs tend to occur on sun-exposed areas, with Merkel cells (MCs) were first described by Friedrich Merkel 3 nearly 80% presenting on the head, neck, and extremities. -
Cryotherapy for Skin Lesions
PATIENT & CAREGIVER EDUCATION Cryotherapy for Skin Lesions This information explains what cryotherapy is and how to care for yourself after your cryotherapy procedure. About Cryotherapy Cryotherapy is a procedure that uses extreme cold (liquid nitrogen) to destroy tissue. It’s often used to treat skin lesions, which are skin growths or patches that don’t look like the skin around them. The lesions can be: Benign (not cancerous) Actinic keratosis. These are precancerous skin cancers that look like scaly patches on your skin, and they can turn into cancer in the future. Superficial skin cancer (skin cancer that’s on the surface of your skin). Cryotherapy also helps save the area around the lesions and to reduce the scarring as much as possible. You don’t have to do anything to get ready for cryotherapy, but you may need to remove makeup, lotion, or powder before your procedure. Your doctor will then spray liquid nitrogen on the area being treated to freeze it. After Cryotherapy The treated area will become red soon after your procedure. It may also blister and swell. If this happens, don’t break open the blister. You may also see clear drainage on the treated area. This is normal. The treated area will heal in about 7 to 10 days. It probably won’t leave a scar. Cryotherapy for Skin Lesions 1/3 Caring for yourself after cryotherapy Starting the day after your procedure, wash the treated area gently with fragrance-free soap and water daily. Put Vaseline ® or Aquaphor ® on the treated area every day for 2 weeks. -
Importance of a Thorough Physical Examination! Muhammad Imran, M.D., Julian Magadan III, M.D., Mehrdad Maz, M.D
Kansas Journal of Medicine 2015 Physical Examination Importance of a Thorough Physical Examination! Muhammad Imran, M.D., Julian Magadan III, M.D., Mehrdad Maz, M.D. University of Kansas Medical Center Department of Internal Medicine Division of Allergy, Clinical Immunology, & Rheumatology Kansas City, KS A 73-year-old white female presented for management of her tophaceous gout, pyoderma gangrenosum, and chronic back pain. On exam, there was an incidental finding of reticular, reddish-brown, non-tender, macular, non-blanching discoloration on her entire back, with a few superficial erosions (see Figure). The patient did not know the duration of her rash. It was neither pruritic nor painful. She denied arthralgia, fever, chills, or other constitutional symptoms. She did not have a history of insect bites, recent foreign travel, falls, or trauma. She frequently used a heating pad to alleviate her chronic back pain. Complete blood count, comprehensive metabolic panel, urine analysis, and inflammatory markers were within normal limits. What is most likely diagnosis? A. Vasculitis B. Livedo Reticularis C. Erythema Ab Igne D. Cutaneous Lupus E. Actinic Keratosis 48 Kansas Journal of Medicine 2015 Physical Examination Correct Answer: C. Erythema Ab Igne Erythema ab igne (EAI), also known as ephelis ignealis or toasted skin syndrome, is an unintentional, unperceived, and self-induced condition, which occurs in individuals who persistently use topical or conventional heat to relieve localized pain or cold.1 It is characterized by chronic, localized, erythematous or hyper-pigmented, reticulated, and net-like skin patches in the affected area. It is usually asymptomatic, but burning and pruritus are reported by some patients.